Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Back to Basics: RheumMadness 2022 Increasing ANA Positivity Scouting Report

University of Chicago School of Medicine: Lauren He, MD; Ana B. Arevalo, MD; & Kichul Ko, MD  |  Issue: May 2022  |  March 3, 2022

Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports for each concept team. These reports are written by rheumatology fellows from

13 programs throughout the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The more your picks match those of our Blue Ribbon Panel of rheumatologists, the more points you get. Learn more about the panel and how the brackets work online.

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn more on the RheumMadness website.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Region: People

Team: Increasing +ANA

Our base article explores how the prevalence of anti-nuclear antibodies (ANA) has changed over the past 25 years. Dinse et al. studied more than 14,000 participants from the U.S. National Health and Nutrition Examination Survey (NHANES) using serum ANA via indirect immunofluorescence (IFA) assays to determine ANA prevalence during three different time periods: 1988–1991, 1999–2004 and 2011–2012. After adjusting for sex, age and race/ethnicity, results show a significant increase in ANA positivity over the past 25 years, with some interesting subgroup differences (see Table 1).1

Interestingly, the increasing prevalence of ANA was apparent in adolescents aged 12–19 years old (P<0.0001) and adults older than 50 years (P=0.001). However, this trend was not seen in adults aged 20–49 years old. The increase in prevalence between the second and third time periods was larger than the increase between the first and the second time periods.

All serum samples were run using IFA on Hep-2 cells. Therefore, differences in testing assays—and possible false positives or negatives—would not account for the trends. The increase in prevalence was seen in both sexes and non-Hispanic whites. Of note, the prevalence of thyroid disease increased across all three time periods, and ANA rates were higher among subjects with thyroid disease compared with those without. These results also showed a positive association between patients who were overweight (i.e., with a body mass index [BMI] of 25≤30 kg/m2) and ANA prevalence in the third period compared with the first period.  

Implications

When considering the future implications of these findings, we first should ask, “What are ANA really, and what is the significance of a positive test?”

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:ANAanti-nuclear antibodiesRheumMadness

Related Articles
    Tasha Art; PureSolution / shutterstock.com

    RheumMadness: An Educational Tournament

    July 15, 2021

    RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal of Kidney Diseases (AJKD) that…

    An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

    February 8, 2022

    According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

    Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report

    March 2, 2022

    Rheumatologists play a critical role in the reproductive health of their patients, but only half of rheumatologists currently ask their patients about reproductive health or family planning issues. A new guideline seeks to change that.

    ‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report

    February 8, 2022

    Neutrophil extracellular traps (NETs) contribute to the pathogenesis of multiple autoimmune diseases. And research has shown that patients with antiphospholipid syndrome (APS) have higher levels of circulating anti-NET antibodies than healthy controls, indicating a potential biomarker.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences